Please login to the form below

Not currently logged in
Email:
Password:

Denali Therapeutics

This page shows the latest Denali Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Lilly signs $960m deal with Rigel to develop RIPK1 inhibitors

Lilly signs $960m deal with Rigel to develop RIPK1 inhibitors

Also working within the RIPK1 inhibitor space is Sanofi and Denali Therapeutics. ... In 2018, Sanofi paid Denali $125m upfront for access to two of the company’s RIPK1 inhibitors.

Latest news

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Where next in Alzheimer’s disease R&D? Where next in Alzheimer’s disease R&D?

    Faced with that litany of failures, researchers are branching out beyond old approaches to amyloid- beta (Abeta) in search of effective therapeutics. ... Denali Therapeutics is collaborating with Sanofi on a drug designed to alleviate inflammatory

  • Deal Watch January 2018

    th. in the top deal makers of 2017, had a busy first week of the New Year, entering into an option and collaboration agreement with Denali Therapeutics paying $155m on agreement ... Acquisition company. 4, 800. Denali Therapeutics/ Takeda Pharmaceutical.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....